Deep Intelligent Pharma
VC Fund
Singapore, Singapore
Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Deep Intelligent Pharma invests in
Stages Deep Intelligent Pharma invests in
Countries Deep Intelligent Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gary Song
|
|||
Hygeia Li
|
|||
Investment Focus
Industry
- Therapeutics 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Product Research 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gary Song
CTO
|
CTO | Total investments: 0 | Find email | |
|
Hygeia Li
Founder and CEO
|
Founder and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Imbioray
|
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases. | $28.8M / Series B / Feb 05, 2026 | |
|
Kinco Biotechnology
|
Kinco Biotech is a gene therapy product developer that develops platforms for gene therapy research and development, including viral vector construction and optimization, large-scale cell culture and virus production processes, quality control systems, and preclinical validation. | Series A / Dec 01, 2025 |
Co-Investors
Longmen Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Deep Intelligent Pharma invest in?
Deep Intelligent Pharma invests primarily in Therapeutics, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Deep Intelligent Pharma?
Public channels for Deep Intelligent Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Deep Intelligent Pharma?
The team at Deep Intelligent Pharma includes Gary Song (CTO) and Hygeia Li (Founder and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
